This has led to the recommendation that all patients with advanced CRC who are being considered for cetuximab orpanitumumab should undergo KRAS testing, and if the cancer bears a mutated KRASgene, they should not receive an antibody that targets EGFR. Here, EGFR is linked to colorectal carcinoma.